» Articles » PMID: 19309396

Prognostic Importance of Epithelial-mesenchymal Transition-related Protein Expression in Gastric Carcinoma

Overview
Journal Histopathology
Date 2009 Mar 25
PMID 19309396
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Epithelial-mesenchymal transition (EMT) is defined as switching of polarized epithelial cells to a migratory fibroblastoid phenotype. EMT is known to be involved in the progression and metastasis of various cancers. The aim was to evaluate the expression of EMT-related proteins in gastric carcinoma (GC).

Methods And Results: The expression of nine EMT-related proteins in the GC tissues of 598 patients was evaluated by immunohistochemistry using a tissue array method. In addition, clinicopathological characteristics and survival were compared with the expression of EMT-related proteins. Loss of epithelial protein and/or acquisition of the expression of mesenchymal proteins were observed in GC. These protein alterations were associated with diffuse type histology, advanced stage and poor patient outcome, respectively. Subjects were divided into three groups according to degree of EMT-related protein alteration. Increases in alteration of EMT-related protein were found to be significantly associated with poorly differentiated histology, higher pTNM stage and unfavourable outcome. Multivariate analysis showed that alterations in the expression of EMT-related proteins were independently associated with poor prognosis.

Conclusions: Loss of epithelial proteins and/or the acquisition of mesenchymal proteins are associated with poorly differentiated histology, advanced stage and poor outcome in GC. The awareness and inhibition of EMT offer a promising target for prevention of metastatic progression and invasion.

Citing Articles

Reduced expression of E-cadherin correlates with poor prognosis and unfavorable clinicopathological features in gastric carcinoma: a meta-analysis.

Lu G, Cai Z, Jiang R, Tong F, Tu J, Chen Y Aging (Albany NY). 2024; 16(12):10271-10298.

PMID: 38870263 PMC: 11236327. DOI: 10.18632/aging.205929.


Next-Generation Sequencing Analysis of Gastric Cancer Identifies the Leukemia Inhibitory Factor Receptor as a Driving Factor in Gastric Cancer Progression and as a Predictor of Poor Prognosis.

Di Giorgio C, Marchiano S, Marino E, Biagioli M, Roselli R, Bordoni M Front Oncol. 2022; 12:939969.

PMID: 35847866 PMC: 9280277. DOI: 10.3389/fonc.2022.939969.


S100A4 Is a Strong Negative Prognostic Marker and Potential Therapeutic Target in Adenocarcinoma of the Stomach and Esophagus.

Treese C, Hartl K, Potzsch M, Dahlmann M, von Winterfeld M, Berg E Cells. 2022; 11(6).

PMID: 35326507 PMC: 8947340. DOI: 10.3390/cells11061056.


Prognostic Lnc-S100B-2 Affects Cell Apoptosis and Microenvironment of Colorectal Cancer through MLLT10 Signaling.

Yi J, Peng F, Zhao J, Gong X J Oncol. 2022; 2022:3565118.

PMID: 35126515 PMC: 8808143. DOI: 10.1155/2022/3565118.


MEK inhibition suppresses metastatic progression of KRAS-mutated gastric cancer.

Yamasaki J, Hirata Y, Otsuki Y, Suina K, Saito Y, Masuda K Cancer Sci. 2021; 113(3):916-925.

PMID: 34931404 PMC: 8898706. DOI: 10.1111/cas.15244.